Kodiak Sciences Inc
Research Kodiak Sciences Inc (KOD) on Bullrun: market cap USD 2.47B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKOD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.47B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 58.16M
- Free cash flow-USD 40.95M
Valuation Snapshot
latest market cap is USD 2.47B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 229.97M | -USD 136.51M | n/a | -4.32 | USD 209.86M | USD 59.18M | USD 157.38M |
| FY2024 | USD 0 | -USD 176.21M | -USD 117.69M | n/a | -3.35 | USD 168.07M | USD 70.35M | USD 150.29M |
| FY2023 | n/a | -USD 260.49M | -USD 195.53M | n/a | -4.97 | USD 285.51M | USD 81.63M | USD 265.78M |
| FY2022 | n/a | -USD 333.82M | -USD 243.48M | n/a | -6.39 | USD 190.43M | USD 87.03M | USD 436.17M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.47B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.73B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 524.63M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 159.52M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 374.53M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 4.39B | n/a | n/a | n/a |
About Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kodiak Sciences Inc's market cap?
Kodiak Sciences Inc's market capitalization is USD 2.47B.
What does Kodiak Sciences Inc do?
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.